Attributes | Values |
---|
rdf:type
| |
http://linked.open...gbank/description
| - A serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc. [PubChem] (en)
|
http://linked.open...y/drugbank/dosage
| |
http://linked.open...generalReferences
| - # Tokunaga S, Takeda Y, Shinomiya K, Hirase M, Kamei C: Effects of some H1-antagonists on the sleep-wake cycle in sleep-disturbed rats. J Pharmacol Sci. 2007 Feb;103(2):201-6. Epub 2007 Feb 8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17287588 (en)
|
http://linked.open...gy/drugbank/group
| |
http://linked.open...ugbank/indication
| - For treatment of perennial and seasonal allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis due to inhalant allergens and foods, mild uncomplicated allergic skin manifestations of urticaria and angioedema, amelioration of allergic reactions to blood or plasma, cold urticaria, dermatographism, and as therapy for anaphylactic reactions adjunctive to epinephrine. (en)
|
http://linked.open...bank/manufacturer
| |
sameAs
| |
Title
| |
adms:identifier
| |
http://linked.open...mechanismOfAction
| - Cyproheptadine competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. Cyproheptadine also competes with serotonin at receptor sites in smooth muscle in the intestines and other locations. Antagonism of serotonin on the appetite center of the hypothalamus may account for Cyproheptadine's ability to stimulate appetite. (en)
|
http://linked.open...drugbank/packager
| |
http://linked.open...outeOfElimination
| - After a single 4 mg oral dose of14C-labelled cyproheptadine HCl in normal subjects, given as tablets 2% to 20% of the radioactivity was excreted in the stools. At least 40% of the administered radioactivity was excreted in the urine. (en)
|
http://linked.open.../drugbank/synonym
| - Cyproheptadine (en)
- Axoprol (en)
- Ciproheptadina (en)
- Cyproheptadin (en)
- Cyproheptadinum (en)
- 1-methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine (en)
- Dihexazin (en)
- Glutodina (en)
- 1-Methyl-4-(5H-dibenzo(a,d)cycloheptenylidene)piperidine (en)
- 4-(5H-Dibenzo(a,D)cyclohepten-5-ylidene)-1-methylpiperidine (en)
- 5-(1-methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene (en)
- 4-Dibenzo[a,D]cyclohepten-5-ylidene-1-methyl-piperidine (en)
- 4-(5-Dibenzo(a,D)cyclohepten-5-ylidine)-1-methylpiperidine (en)
|
http://linked.open.../drug/hasAHFSCode
| |
http://linked.open...k/foodInteraction
| - Avoid alcohol. (en)
- Take with food. (en)
|
http://linked.open.../drugbank/mixture
| |
http://linked.open...nk/proteinBinding
| |
http://linked.open...ogy/drugbank/salt
| |
http://linked.open...ynthesisReference
| - Engelhardt, E.L.; U S . Patent 3,014,911; December 26, 1961; assigned to Merck & Co., Inc. (en)
|
foaf:page
| |
http://linked.open...ugbank/IUPAC-Name
| |
http://linked.open...gy/drugbank/InChI
| |
http://linked.open...Molecular-Formula
| |
http://linked.open.../Molecular-Weight
| |
http://linked.open...noisotopic-Weight
| |
http://linked.open...y/drugbank/SMILES
| |
http://linked.open.../Water-Solubility
| |
http://linked.open...ogy/drugbank/logP
| |
http://linked.open...ogy/drugbank/logS
| |
http://linked.open...l/drug/hasATCCode
| |
http://linked.open...nd-Acceptor-Count
| |
http://linked.open...-Bond-Donor-Count
| |
http://linked.open...drugbank/InChIKey
| |
http://linked.open...urface-Area--PSA-
| |
http://linked.open...nk/Polarizability
| |